Guardian

Weight-loss drug cuts heart attack risk regardless of kilograms shed, study finds

Mirage News

Weight Loss Drug Benefits Heart Irrespective of Loss

New Scientist

Wegovy has heart health benefits even if weight loss is minimal

Metaculus

Large obesity drop in OECD country by 2030

SciTech Daily

Ozempic And Wegovy Scientists Uncover New Risks Of Popular Weight Loss Miracle Drugs

Why weight loss drugs are not a 'miracle' cure for obesity

Axios

Wegovy New Uses Cost Safety

How weight-loss wonder drugs are redefining the way our bodies work

EuroNews

The Telegraph

Weight Loss Jabs Good For Not Obese

Daily Mail

The biggest heart health breakthrough since statins? Largest study to date shows Ozempic can dramatically lower risk of major heart problems regardless of weight lost

Daily Mirror

Wegovy and Ozempic shown to slash risk of heart attack and stroke

The Sun

Captcha Page

The New York Times

Wegovy Cardiovascular Benefits Weight Loss Study.Html

The Times

Ozempic cuts heart attack risk  even if you dont lose weight

Independent

Weight-loss jabs boost heart health no matter how much fat is lost

Medicalxpress

Semaglutide helps heart regardless of how much weight lost, study reveals

A study of 17,604 people aged 45 and over found that semaglutide, the active ingredient in Wegovy and Ozempic, reduced the risk of major cardiac events by 20 percent regardless of participants' starting weight or amount of weight lost during treatment.</span

A study of 17,604 people aged 45 and over found that semaglutide, the active ingredient in Wegovy and Ozempic, reduced the risk of major cardiac events by 20 percent regardless of participants' starting weight or amount of weight lost during treatment.

Researchers discovered that people with a BMI of 27, which represents the average for UK adults and classifies them as overweight but not obese, experienced similar cardiovascular benefits as those with the highest BMI scores in the severely obese category.</span

Researchers discovered that people with a BMI of 27, which represents the average for UK adults and classifies them as overweight but not obese, experienced similar cardiovascular benefits as those with the highest BMI scores in the severely obese category.

The study found that shrinking waist circumference accounted for approximately one-third of semaglutide's cardiovascular benefits, while the remaining two-thirds of the heart health improvements remain unexplained by current medical understanding.</span

The study found that shrinking waist circumference accounted for approximately one-third of semaglutide's cardiovascular benefits, while the remaining two-thirds of the heart health improvements remain unexplained by current medical understanding.

Professor John Deanfield from University College London stated that abdominal fat poses greater cardiovascular risks than overall weight, explaining why waist size reduction showed stronger correlation with heart benefits than total weight loss.</span

Professor John Deanfield from University College London stated that abdominal fat poses greater cardiovascular risks than overall weight, explaining why waist size reduction showed stronger correlation with heart benefits than total weight loss.

The research suggests that cardiovascular benefits from semaglutide begin appearing within the first 20 weeks of treatment, before significant weight loss occurs, indicating the drug has direct effects on heart disease beyond weight reduction mechanisms.</span

The research suggests that cardiovascular benefits from semaglutide begin appearing within the first 20 weeks of treatment, before significant weight loss occurs, indicating the drug has direct effects on heart disease beyond weight reduction mechanisms.

The NHS currently limits access to weight loss injections to 240,000 people with highest need over three years, while experts suggest the findings support broadening access beyond strict BMI restrictions for cardiovascular disease prevention.</span

The NHS currently limits access to weight loss injections to 240,000 people with highest need over three years, while experts suggest the findings support broadening access beyond strict BMI restrictions for cardiovascular disease prevention.

Ozempic Cuts Heart Disease Risk 20% Regardless of Weight Loss

Ozempic Cuts Heart Disease Risk 20% Regardless of Weight Loss

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters

Ozempic Cuts Heart Disease Risk 20% Regardless of Weight Loss

Ozempic Cuts Heart Disease Risk 20% Regardless of Weight Loss

Sign Up for Our Free NewslettersSign Up for Our Free Newsletters

Sign Up for Our Free Newsletters
Sign Up for Our Free Newsletters